STOCK TITAN

[SCHEDULE 13G] Xenon Pharmaceuticals Inc. Passive Investment Disclosure (>5%)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Wellington Management has disclosed a sizeable institutional stake in Xenon Pharmaceuticals Inc. (XENE). As of December 31, 2025, Wellington entities report beneficial ownership of 4,764,779 shares of Xenon common stock, representing about 6.17% of the outstanding shares.

Across the listed Wellington entities, there is no sole voting or dispositive power; voting and investment decisions are reported as shared over most of these shares. The filing explains that the securities are owned of record by Wellington investment-adviser clients, who receive dividends and sale proceeds, while no single client holds more than five percent of the class. Wellington certifies the position is held in the ordinary course of business and not for the purpose of influencing control of Xenon.

Positive

  • None.

Negative

  • None.

Insights

Wellington reports a 6.17% institutional stake in Xenon held for ordinary-course investment.

Wellington Management Group LLP and related entities report beneficial ownership of 4,764,779 Xenon common shares, or about 6.17% of the class as of December 31, 2025. Voting and dispositive powers are reported as shared, with no sole authority at the parent level.

The shares are owned of record by clients of several Wellington investment advisers, which means economic benefits like dividends and sale proceeds accrue to those clients. The filing states no single client has rights over more than five percent of the class, dispersing effective control.

The certification that the position is held in the ordinary course of business and not with the purpose or effect of changing or influencing control frames this as a standard institutional investment. Future ownership updates would typically appear in subsequent beneficial ownership reports if Wellington’s percentage changes materially.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Management Company LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Xenon Pharmaceut

NASDAQ:XENE

XENE Rankings

XENE Latest News

XENE Latest SEC Filings

XENE Stock Data

3.28B
76.41M
0.14%
111.41%
8.96%
Biotechnology
Pharmaceutical Preparations
Link
Canada
BURNABY